Dublin, May 31, 2021 (GLOBE NEWSWIRE) -- The "Global Generic Drugs Market 2020-2025" report has been added to ResearchAndMarkets.com's offering.
The global market for generic drugs should grow from $411.6 billion in 2020 to $650.3 billion by 2025, at a compound annual growth rate (CAGR) of 9.6% for the period of 2020-2025.
The nature and structure of the generic drug industry is discussed, with profiles of the leading 20+ generic drug companies and an update on M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of the products involved.
This report is being published at a time when the pharmaceutical industry faces challenges and changes more radical than any it has faced in the last half-century. The worldwide economic recession in 2008 has had a profound impact on an industry that is normally resilient to the usual ups and downs of commercial life. Apart from the sometimes painful process of cutting costs and restructuring, the industry has had to confront the fact that its trading environment has fundamentally changed because all its customers are now aware of prices.
At this critical time, the pharmaceutical world has also endured a phase for which the label "patent cliff" was coined. A stream of blockbuster drugs has begun losing their patent protection, and R&D pipelines have not been able to produce a satisfactory supply of replacements. The doors have been thrown open to generic drug producers to do what they do best: provide low-cost alternatives.
And there is an added complexity. Over the past two decades, advances in biotechnology have led to the introduction of a generation of biotherapeutic agents that are often more efficacious than traditional small-molecule drugs at treating their target diseases. The earliest of these biotherapeutics are now losing their patent protection, and this offers yet another opportunity for generic copies - although this is a technically fraught area, as will be seen. In fact, the challenges facing "originator" companies - the major purveyors of own-brand pharmaceuticals - are matched by those confronting generic drug suppliers.
Suppliers of generic drugs relied initially on low cost as their main market advantage. It became a potent argument, as the government health departments in most European countries operating national health schemes began to introduce measures designed to curb pharmaceutical expenditure. In the U.S., developments in managed care had a similar effect. Everywhere, these cost-cutting exercises favored generics.
However, the low-cost argument that had been the generic products' main rationale acted against the commercial promise of this industry sector. This occurred partly because the attractiveness (and thus high-volume sales potential) of blockbuster drugs remained in place after these drugs lost their patent cover. Generic drug companies vied with each other to introduce low-cost copies, and they were driven to undercut each other to the point where a year after patent expiry on the original brand, the mean price of copy products was merely 20% or less of the original.
Partly, too, generic price competition was fueled by government reimbursement measures, which favored low-cost drugs and thus tended to trigger further price cutting among the generic drug contenders.
This development had two far-reaching effects. First, it began to weed out the weaker generic drug companies in favor of companies that had the means and the resolve to exist in an environment where profit margins were severely cut, sometimes to less than 10%. One of the survival strategies adopted by these manufacturers has been to widen their appeal beyond mere cost-cutting, to include, for example, "super generics" products with added value, often in the form of special delivery formulations.
Company profiles of the leading players operating in the global generic drugs market including Aspen, Cipla, Lupin, Pfizer, Sanofi, Sun Pharmaceuticals and Teva Pharmaceuticals
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
Recent History of the Generic Drug Industry
Chapter 4 Impact of COVID-19
Short-Term Impact on the Pharma Industry
Long-Term Impact on the Pharma Industry
Impact of COVID-19 on the Market for Generic Drugs
Impact on the Supply Chain
Chapter 5 The New Generics Era
The Patent Cliff
Types of Generic Drugs
ANDA (Abbreviated New Drug Application) Approvals
Chapter 6 Major Issues Within the Market for Generic Drugs
Regulation of Biosimilars
Evolving Situation in the U.S.
Defensive Strategies Used by Big Pharma
Authorized Generic Drugs
Changing Climate for Generics
Situation in Europe
Patents and IP
Supplementary Protection Certificates
Chapter 7 Global Market for Generic Drugs
Global Pharmaceutical Market: Brand Name and Generic Drugs
Global Market for Generic Drugs
Market Opportunities by Product Class
Market Shares of Pharmaceutical Drugs by Therapeutic Area
Chapter 8 Market Breakdown by Region
Chapter 9 Industry Trends
Structure of the Generic Drug Industry
Recent Mergers and Acquisitions
Brand Name Company Involvement
Chapter 10 Company Profiles
Sandoz International Gmbh
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Chapter 11 Other International Companies
Aurobindo Pharma Ltd.
Dr. Reddy's Laboratories Ltd.
Egis Pharmaceuticals Plc
Par Pharmaceutical Inc.
Strides Shasun Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/kakekz
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900